FDA clears Glenmark’s HER2+ cancer drug for Phase I trial
European Pharmaceutical Review | January 03, 2017
The US Food and Drug Administration (FDA) cleared Glenmark Pharmaceutical’s investigational new drug (IND) application to initiate a phase I study of its lead candidate, GBR 1302-BEAT, in patients with HER2+ cancers.